Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

BackgroundPreclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with immunotherapy.MethodsThis investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with untr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Saba S. Shaikh, Yan Zang, Janel Hanmer, Hong Wang, Yan Lin, Diwakar Davar, Hassane M. Zarour, John M. Kirkwood, Yana G. Najjar
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2022-11-01
Σειρά:	Frontiers in Oncology
Θέματα:	immunotherapy targeted therapy BRAF melanoma metastatic clinical trial
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1022496/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!